Palo Alto Investors Llc acquired 59,287 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 13.73%. The …
Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $88.93 to a high of $90.24. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $88.72 on volume of 1.1 …
... play on BioMarin Pharmaceutical (BMRN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $85 covered call for a net debit in the $83.20 area. That is also the break-even stock price for the …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN
Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN): -Earnings: -$44.15 million in Q1 vs. -$16.29 million in the same period last year. -EPS: -$0.26 in Q1 vs. -$0.09 in the same period last year. -Analysts projected …
10 stocks we like better than BioMarin Pharmaceutical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the …
BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017. BioMarin (BMRN) ...